Abstract
Among candidate treatment options for COVID-19, propolis, produced by honey bees from bioactive plant exudates, has shown potential against viral targets and has demonstrated immunoregulatory properties. We conducted a randomized, controlled, open-label, single center trial, with a standardized propolis product (EPP-AF) on hospitalized adult COVID-19 patients. Patients received standard care plus propolis at an oral dose of 400mg/day (n=40) or 800mg/day (n=42) for seven days, or standard care alone (n=42). Standard care included all necessary interventions, as determined by the attending physician. The primary end point was the time to clinical improvement defined as the length of hospital stay or oxygen therapy dependency. Secondary outcomes included acute kidney injury and need for intensive care or vasoactive drugs. Time in the hospital after intervention was significantly shortened in both propolis groups compared to the controls; median 7 days with 400mg/day and 6 days with 800mg/day, versus 12 days for standard care alone. Propolis did not significantly affect the need for oxygen supplementation. With the higher dose, significantly fewer patients developed acute kidney injury than in the controls (2 versus 10 of 42 patients). Propolis as an adjunct treatment was safe and reduced hospitalization time. The registration number for this clinical trial is: NCT04480593 (20/07/2020).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04480593
Funding Statement
The natural products company Apis Flora Indl. Coml. Ltda. in Ribeirao Preto, Sao Paulo, Brazil, provided funding and the propolis capsules for patient treatment. The D'Or Institute for Research and Education (IDOR) and Hospital Sao Rafael in Salvador, Bahia, Brazil, provided funding, infrastructure, and staff for assistance with the research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was approved by the Brazilian Committee of Ethics in Human Research (Registration number 31099320.6.0000.0048)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Relevant data is available in the manuscript file. If additional data is needed, it can be obtained from the Corresponding Author: Marcelo Augusto Duarte Silveira, MD, PhD, D'Or Institute for Research and Education (IDOR), Hospital Sao Rafael, Sao Rafael Avenue, 2152 - Sao Marcos, Salvador - Bahia, 41253-190, Brazil (marceloadsilveira@gmail.com)
